Literature DB >> 20111070

ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.

J Wu, F Meng, Y Ying, Z Peng, L Daniels, W G Bornmann, A Quintás-Cardama, D Roulston, M Talpaz, L F Peterson, N J Donato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20111070      PMCID： PMC4677994          DOI： 10.1038/leu.2009.300

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Authors:  Geoffrey A Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

2.  A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

Authors:  Kiranmai Gumireddy; Stacey J Baker; Stephen C Cosenza; Premila John; Anthony D Kang; Kimberly A Robell; M V Ramana Reddy; E Premkumar Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

3.  Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Authors:  Ji Wu; Feng Meng; Ling-Yuan Kong; Zhenghong Peng; Yunming Ying; William G Bornmann; Bryant G Darnay; Betty Lamothe; Hanshi Sun; Moshe Talpaz; Nicholas J Donato
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

4.  Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Authors:  Ji Wu; Feng Meng; Henry Lu; Ling Kong; William Bornmann; Zhenghong Peng; Moshe Talpaz; Nicholas J Donato
Journal:  Blood       Date:  2008-01-30       Impact factor: 22.113

5.  Metabolism and disposition of dasatinib after oral administration to humans.

Authors:  Lisa J Christopher; Donghui Cui; Chiyuan Wu; Roger Luo; James A Manning; Samuel J Bonacorsi; Michael Lago; Alban Allentoff; Francis Y F Lee; Betty McCann; Susan Galbraith; Donald P Reitberg; Kan He; Anthony Barros; Anne Blackwood-Chirchir; W Griffith Humphreys; Ramaswamy A Iyer
Journal:  Drug Metab Dispos       Date:  2008-04-17       Impact factor: 3.922

6.  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

Authors:  Elias Jabbour; Hagop Kantarjian; Dan Jones; Megan Breeden; Guillermo Garcia-Manero; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Jorge Cortes
Journal:  Blood       Date:  2008-04-10       Impact factor: 22.113

7.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

8.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Authors:  Uwe Rix; Oliver Hantschel; Gerhard Dürnberger; Lily L Remsing Rix; Melanie Planyavsky; Nora V Fernbach; Ines Kaupe; Keiryn L Bennett; Peter Valent; Jacques Colinge; Thomas Köcher; Giulio Superti-Furga
Journal:  Blood       Date:  2007-08-24       Impact factor: 22.113
  8 in total
  7 in total

1.  Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Valentina Minieri; Marco De Dominici; Patrizia Porazzi; Samanta A Mariani; Orietta Spinelli; Alessandro Rambaldi; Luke F Peterson; Pierluigi Porcu; Marja T Nevalainen; Bruno Calabretta
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

2.  Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

Authors:  Don L Gibbons; Sabrina Pricl; Paola Posocco; Erik Laurini; Maurizio Fermeglia; Hanshi Sun; Moshe Talpaz; Nicholas Donato; Alfonso Quintás-Cardama
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

3.  Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.

Authors:  Nathalie Carayol; Eliza Vakana; Antonella Sassano; Surinder Kaur; Dennis J Goussetis; Heather Glaser; Brian J Druker; Nicholas J Donato; Jessica K Altman; Sharon Barr; Leonidas C Platanias
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.

Authors:  Eliza Vakana; Jessica K Altman; Heather Glaser; Nicholas J Donato; Leonidas C Platanias
Journal:  Blood       Date:  2011-10-21       Impact factor: 22.113

Review 5.  The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Priyanka A Pophali; Mrinal M Patnaik
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360

6.  Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.

Authors:  Eliza Vakana; Ahmet Dirim Arslan; Amy Szilard; Jessica K Altman; Leonidas C Platanias
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

Review 7.  Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.

Authors:  Meghan E Breen; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2014-12-23       Impact factor: 5.100
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.